Liminatus Pharma, Inc. (LIMN): Nasdaq/NYSE listing notice — Liminatus Pharma receives Nasdaq bid price deficiency notice; 180 days to regain compliance

Liminatus Pharma, Inc.

Received Nasdaq deficiency notice on Jan 15, 2026 for failing to maintain $1 minimum bid price for 30 consecutive business days.
Has 180 calendar days, until July 14, 2026, to regain compliance by achieving $1 closing bid for 10 consecutive days.
If non-compliant after period, may seek additional time; reverse split must be completed 10 business days before deadline.
Common stock continues trading under symbol LIMN during compliance period.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Liminatus Pharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

January 15, 2026, Liminatus Pharma, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”) which requires listed securities to maintain a minimum bid price of $1 per share. The notification has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on Nasdaq under the symbol “

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Liminatus Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-006619

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.